Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edilberto Benitez

Cardiovascular Disease Gainesville, FL Medical Doctor

NPI 1104168673 CMS profile 1384364

1515 Sw Archer Rd, Ste 221, Gainesville, FL 32608

Open in the dashboard

General payments

$43,759

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edilberto Benitez of Gainesville, FL is reported in the CMS Open Payments database as having received $43,759 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,738 88
2024 General $2,177 59
2023 General $1,504 44
2022 General $1,837 50
2021 General $706 19
2020 General $9,963 7
2019 General $21,835 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edilberto Benitez
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Edilberto Benitez were reported at $5,738. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Edilberto Benitez Cardiovascular Disease median Middle half National median
2019 $21,835 $450 $127–$1,392 $163
2020 $9,963 $242 $77–$751 $114
2021 $706 $335 $101–$1,037 $132
2022 $1,837 $395 $121–$1,211 $149
2023 $1,504 $443 $136–$1,283 $160
2024 $2,177 $450 $136–$1,323 $164
2025 $5,738 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $15,386 47 payments
  2. Boston Scientific Corporation $10,455 12 payments
  3. Abbott Laboratories $5,069 6 payments
  4. Medtronic, Inc. $4,969 60 payments
  5. Medical Device Business Services, Inc. $1,176 7 payments
  6. Biosense Webster, Inc. $1,018 15 payments
  7. CVRx, Inc. $784 14 payments
  8. Abiomed $783 9 payments
  9. E.R. Squibb & Sons, L.L.C. $414 15 payments
  10. Novartis Pharmaceuticals Corporation $360 21 payments
  11. Other $3,346 119 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $23,083 5 payments
  2. Food and Beverage $12,445 294 payments
  3. Travel and Lodging $8,144 23 payments
  4. Education $87 3 payments
Products named General payments · program years 2019–2025
  1. GENERAL BRADY $5,000 1 payment
  2. GENERAL - BRADY $5,000 1 payment
  3. Assurity Pacemaker $2,375 1 payment
  4. Carto 3 System $1,176 7 payments
  5. Carto 3 $837 13 payments
  6. Barostim Neo System $784 14 payments
  7. VERQUVO $520 20 payments
  8. LINQ II $501 11 payments
  9. Impella $472 6 payments
  10. AFFERA MAPPING SYSTEM $345 4 payments
  11. Other $7,080 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,244

Median for Cardiology: 2,533

Drug cost

$483,396

Median for Cardiology: $485,213

Branded share of claims

35%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 238 $277,720
Entresto Sacubitril/Valsartan Brand 48 $80,764
Xarelto Rivaroxaban Brand 58 $59,343
Dofetilide Generic 90 $19,086
Farxiga Dapagliflozin Propanediol Brand 12 $14,783
Ozempic Semaglutide Brand 14 $13,440
Multaq Dronedarone Hcl Brand 15 $9,591
Valsartan Generic 57 $1,175
Atorvastatin Calcium Generic 98 $1,026
Sotalol Sotalol Hcl Brand 28 $827

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$316,039

Medicare's payments for the services billed

Medicare patients

1,300

Average age 78

Services billed

4,501

567 women, 733 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 65%
Ischemic heart disease 59%
Arthritis 57%
Heart failure 45%
Chronic kidney disease 41%
Diabetes 40%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $160
$160 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $145
$145 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $101
$101 12 —
Repatha
  • Amgen Inc. $95
$95 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record